|
BRIEF-Vectura's asthma drug meets main goal in mid-stage trial
Reuters Dec 11 (Reuters) – Vectura Group Plc. * Positive phase IIb/III results for VR475 in asthma. * Investigational drug/device combination VR475 met primary endpoint and has shown significant clinical benefit in a phase IIb/III trial in severe asthma patients. |
View full post on asthma – Google News